PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2017-03-31
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $16.15K, a 98.78% decline from fiscal 2014.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $1.33M, a 18861.43% increase from fiscal 2013.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $7.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-31 |
| 2015-12-31 | $16.15K 10-K · filed 2017-03-31 |
| 2014-12-31 | $1.33M 10-K · filed 2017-03-31 |
| 2013-12-31 | $7.00K 10-K · filed 2016-03-30 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-12 |
| 2011-12-31 | $108.58K 10-K · filed 2014-03-13 |
| 2010-12-31 | $143.70K 10-K · filed 2013-03-14 |